Recombinant Protein

Recombinant Protein designates molecules synthesised in living organisms through genetic engineering, where genes encoding desired proteins are inserted into host cells that subsequently produce the target protein at industrial quantities. This biotechnology foundation enables manufacturing of therapeutic proteins, enzymes, and research reagents with unprecedented purity, consistency, and scalability, fundamentally transforming pharmaceutical development and production.

The recombinant protein production process begins with gene synthesis or cloning, followed by insertion into expression vectors containing regulatory elements. These constructs are introduced into host organisms ranging from bacteria for simple proteins to mammalian cell lines for complex therapeutics requiring specific post-translational modifications. Fermentation or cell culture processes amplify protein production, followed by purification steps including chromatography and filtration that isolate target proteins from cellular contaminants. Recombinant protein therapeutics represent the fastest-growing pharmaceutical segment, encompassing insulin, growth factors, clotting factors, enzymes, and monoclonal antibodies. The biopharmaceutical industry invests heavily in expression system development, with companies engineering cell lines achieving productivity exceeding 10 grams per litre. Biosimilar development relies entirely on recombinant technology. Regulatory agencies mandate comprehensive characterisation including amino acid sequence verification, glycosylation profiling, and host cell protein analysis.